BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Leukemia AND PDGFRB, JTK12, 5159, P09619, ENSG00000113721, PDGF-R-beta, PDGFR1, CD140B, PDGFR, CD140b AND Prognosis
44 results:

  • 1. World Health Organization and International Consensus Classification of eosinophilic disorders: 2024 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2024 May; 99(5):946-968. PubMed ID: 38551368
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. The novel TERF2::pdgfrb fusion gene enhances tumorigenesis via pdgfrb/STAT5 signalling pathways and sensitivity to TKI in ph-like ALL.
    Xu GF; Zeng Z; Zhang ZB; Zhang XM; Wang M; Xiao Q; Li J; Xie XQ; He S; Fu HH; Liu Y; Yang ZL; Chen Y; Shi J; Wang B; Qiu HY; Zhou Q; Liu Y; Chen SN
    J Cell Mol Med; 2024 Feb; 28(3):e18114. PubMed ID: 38323741
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. SHIP1 Is Present but Strongly Downregulated in T-ALL, and after Restoration Suppresses leukemia Growth in a T-ALL Xenotransplantation Mouse Model.
    Ehm P; Rietow R; Wegner W; Bußmann L; Kriegs M; Dierck K; Horn S; Streichert T; Horstmann M; Jücker M
    Cells; 2023 Jul; 12(13):. PubMed ID: 37443832
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. [Research Progress of m6A Demethylase FTO and Its Inhibitors in Acute Myeloid leukemia --Review].
    Fang ZH; Zheng SY; Feng WY
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Jun; 31(3):902-906. PubMed ID: 37356958
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Rapid molecular response to dasatinib in Ph-like acute lymphoblastic leukemia patients with ABL1 rearrangements: case series and literature review.
    Tan KW; Zhu YY; Qiu QC; Wang M; Shen HJ; Huang SM; Cao HY; Wan CL; Li YY; Dai HP; Xue SL
    Ann Hematol; 2023 Sep; 102(9):2397-2402. PubMed ID: 37103615
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. [Prognostic analysis of children with Philadelphia chromosome-like acute lymphoblastic leukemia common genes].
    Hu WD; Li B; Su SF; Liu YF; Liu W; Zhang WL; Zuo WL; Yu RH
    Zhonghua Er Ke Za Zhi; 2023 May; 61(5):446-452. PubMed ID: 37096265
    [No Abstract]    [Full Text] [Related]  

  • 7. Radotinib inhibits multiple myeloma cell proliferation via suppression of STAT3 signaling.
    Heo SK; Noh EK; Seo HJ; Lee YJ; Koh S; Min YJ; Choi Y; Jo JC
    PLoS One; 2022; 17(5):e0265958. PubMed ID: 35503759
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. t(5;12)(q31;p13)/ETV6::ACSL6 and t(6;9)(p23;q34)/DEK::NUP214 concurrence in acute myeloid leukemia: an unusual association of two rare abnormalities.
    Baldazzi C; Luatti S; Marzocchi G; Grassi A; Cavo M; Testoni N
    Cancer Genet; 2022 Apr; 262-263():35-39. PubMed ID: 34979355
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. World Health Organization-defined eosinophilic disorders: 2022 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2022 Jan; 97(1):129-148. PubMed ID: 34533850
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Beneficial tyrosine kinase inhibitor therapy in a patient with relapsed BCR-ABL1-like acute lymphoblastic leukemia with CCDC88C-pdgfrb fusion.
    Oya S; Morishige S; Ozawa H; Sasaki K; Semba Y; Yamasaki Y; Nakamura T; Aoyama K; Seki R; Mouri F; Osaki K; Miyamoto T; Maeda T; Nagafuji K
    Int J Hematol; 2021 Feb; 113(2):285-289. PubMed ID: 32951102
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Update on CML-Like Disorders.
    Cross NCP
    Clin Lymphoma Myeloma Leuk; 2020 Sep; 20 Suppl 1():S101-S102. PubMed ID: 32862848
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. The incidence, genetic characteristics, and prognosis of leukemia with concurrent pathogenic fusion genes: a series of 25 cases from a large cohort of leukemia patients.
    Chen X; Wang F; Wang T; Zhang Y; Ma X; Yuan L; Teng W; Guo L; Liu M; Liu M; Chen J; Nie D; Zhang Y; Zhou X; Wang M; Chen KN; Zhu P; Liu H
    Cancer Gene Ther; 2020 Feb; 27(1-2):89-97. PubMed ID: 31645680
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. [The 8p11 myeloproliferative syndrome: a review of recent literature].
    Kirito K
    Rinsho Ketsueki; 2019; 60(9):1157-1165. PubMed ID: 31597839
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. World Health Organization-defined eosinophilic disorders: 2019 update on diagnosis, risk stratification, and management.
    Shomali W; Gotlib J
    Am J Hematol; 2019 Oct; 94(10):1149-1167. PubMed ID: 31423623
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Coexisting of bone marrow fibrosis, dysplasia and an X chromosomal abnormality in chronic neutrophilic leukemia with CSF3R mutation: a case report and literature review.
    Wu XB; Wu WW; Zhou Y; Wang X; Li J; Yu Y
    BMC Cancer; 2018 Mar; 18(1):343. PubMed ID: 29587671
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Midostaurin for the treatment of adult patients with newly diagnosed acute myeloid leukemia that is FLT3 mutation-positive.
    Garcia JS; Percival ME
    Drugs Today (Barc); 2017 Oct; 53(10):531-543. PubMed ID: 29286055
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. World Health Organization-defined eosinophilic disorders: 2017 update on diagnosis, risk stratification, and management.
    Gotlib J
    Am J Hematol; 2017 Nov; 92(11):1243-1259. PubMed ID: 29044676
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Deregulation of kinase signaling and lymphoid development in EBF1-pdgfrb ALL leukemogenesis.
    Welsh SJ; Churchman ML; Togni M; Mullighan CG; Hagman J
    Leukemia; 2018 Jan; 32(1):38-48. PubMed ID: 28555080
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. CD36-positive B-lymphoblasts Predict Poor Outcome in Children With B-lymphoblastic leukemia.
    Newton JG; Horan JT; Newman S; Rossi MR; Ketterling RP; Park SI
    Pediatr Dev Pathol; 2017 Jun; 20(3):224-231. PubMed ID: 28521628
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. Myeloid neoplasms with eosinophilia.
    Reiter A; Gotlib J
    Blood; 2017 Feb; 129(6):704-714. PubMed ID: 28028030
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 3.